AU2008226639B2 - Compounds for the treatment of hepatitis C - Google Patents

Compounds for the treatment of hepatitis C Download PDF

Info

Publication number
AU2008226639B2
AU2008226639B2 AU2008226639A AU2008226639A AU2008226639B2 AU 2008226639 B2 AU2008226639 B2 AU 2008226639B2 AU 2008226639 A AU2008226639 A AU 2008226639A AU 2008226639 A AU2008226639 A AU 2008226639A AU 2008226639 B2 AU2008226639 B2 AU 2008226639B2
Authority
AU
Australia
Prior art keywords
pct
cyclohexyl
methoxy
benzazepine
indolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008226639A
Other languages
English (en)
Other versions
AU2008226639A1 (en
Inventor
John A. Bender
Min Ding
Robert G. Gentles
Katharine A. Grant-Young
Ying Han
Piyasena Hewawasam
Thomas W. Hudyma
John F. Kadow
Yong Tu
Kap-Sun Yeung
Xiaofan Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2008226639A1 publication Critical patent/AU2008226639A1/en
Application granted granted Critical
Publication of AU2008226639B2 publication Critical patent/AU2008226639B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2008226639A 2007-03-14 2008-03-05 Compounds for the treatment of hepatitis C Ceased AU2008226639B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89488707P 2007-03-14 2007-03-14
US60/894,887 2007-03-14
US98947407P 2007-11-21 2007-11-21
US60/989,474 2007-11-21
PCT/US2008/055893 WO2008112473A1 (en) 2007-03-14 2008-03-05 Compounds for the treatment of hepatitis c

Publications (2)

Publication Number Publication Date
AU2008226639A1 AU2008226639A1 (en) 2008-09-18
AU2008226639B2 true AU2008226639B2 (en) 2012-07-19

Family

ID=39477552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008226639A Ceased AU2008226639B2 (en) 2007-03-14 2008-03-05 Compounds for the treatment of hepatitis C

Country Status (19)

Country Link
US (1) US7547690B2 (enExample)
EP (1) EP2118109B1 (enExample)
JP (1) JP5232178B2 (enExample)
KR (1) KR20100015304A (enExample)
CN (1) CN101657455B (enExample)
AR (1) AR065772A1 (enExample)
AU (1) AU2008226639B2 (enExample)
BR (1) BRPI0808763A2 (enExample)
CA (1) CA2681093A1 (enExample)
CL (1) CL2008000751A1 (enExample)
CO (1) CO6180426A2 (enExample)
EA (1) EA016614B1 (enExample)
IL (1) IL200905A0 (enExample)
MX (1) MX2009009473A (enExample)
NZ (1) NZ579342A (enExample)
PE (1) PE20090648A1 (enExample)
TW (1) TW200848058A (enExample)
WO (1) WO2008112473A1 (enExample)
ZA (1) ZA200906129B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2209789B1 (en) * 2007-11-20 2011-11-16 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
CN101910177B (zh) 2007-12-24 2013-08-28 泰博特克药品公司 作为丙型肝炎病毒抑制剂的大环吲哚
US8178523B2 (en) * 2008-03-27 2012-05-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
KR20100126560A (ko) * 2008-03-27 2010-12-01 브리스톨-마이어스 스큅 컴퍼니 피롤리딘 융합된 인돌로벤자디아제핀 ｈｃｖ ｎｓ5ｂ 억제제
US8138171B2 (en) * 2008-03-27 2012-03-20 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
AU2010328419A1 (en) * 2009-12-07 2012-06-21 Targacept, Inc. 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
WO2014011863A1 (en) * 2012-07-12 2014-01-16 Targacept, Inc. Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
AU2017233739A1 (en) 2016-03-15 2018-09-20 Bayer Cropscience Aktiengesellschaft Substituted sulfonyl amides for controlling animal pests
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CN110028510A (zh) * 2019-05-22 2019-07-19 南京合巨药业有限公司 一种3-甲基-3,6-二氮杂-双环[3,1,1]庚烷二盐酸盐的制备方法
EP4055010A1 (de) 2019-11-07 2022-09-14 Bayer Aktiengesellschaft Substituierte sulfonylamide zur bekämpfung tierischer schädlinge
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007136982A1 (en) * 2006-05-17 2007-11-29 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080399A1 (ja) 2004-02-24 2005-09-01 Japan Tobacco Inc. ４環縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
RU2007119562A (ru) 2004-10-26 2008-12-10 Институто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа (It) Тетрациклические производные индолов в качестве противовирусных агентов
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
DE602007006796D1 (de) * 2006-05-25 2010-07-08 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007136982A1 (en) * 2006-05-17 2007-11-29 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Also Published As

Publication number Publication date
US7547690B2 (en) 2009-06-16
ZA200906129B (en) 2010-11-24
US20080227769A1 (en) 2008-09-18
EP2118109A1 (en) 2009-11-18
BRPI0808763A2 (pt) 2014-09-16
JP5232178B2 (ja) 2013-07-10
CA2681093A1 (en) 2008-09-18
NZ579342A (en) 2011-07-29
CL2008000751A1 (es) 2008-07-25
KR20100015304A (ko) 2010-02-12
EA016614B1 (ru) 2012-06-29
EA200901241A1 (ru) 2010-02-26
WO2008112473A1 (en) 2008-09-18
CO6180426A2 (es) 2010-07-19
EP2118109B1 (en) 2014-11-26
CN101657455A (zh) 2010-02-24
TW200848058A (en) 2008-12-16
AR065772A1 (es) 2009-07-01
IL200905A0 (en) 2010-05-17
AU2008226639A1 (en) 2008-09-18
CN101657455B (zh) 2013-02-06
JP2010521476A (ja) 2010-06-24
PE20090648A1 (es) 2009-05-29
MX2009009473A (es) 2009-09-15

Similar Documents

Publication Publication Date Title
EP2118109B1 (en) Compounds for the treatment of hepatitis c
AU2007253998B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2118108B1 (en) Compounds for the treatment of hepatitis c
US7521443B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2209789B1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
EP2121697B1 (en) Compounds for the treatment of hepatitis c
EP2518073B1 (en) Compounds for the treatment of Hepatitis C
EP2215095B1 (en) Cyclopropyl fused indolobenzazepine derivatives for the treatment of hepatitis c
EP2401280B1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
ES2370121T3 (es) Compuestos para el tratamiento de la hepatitis c.
HK1122814B (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired